Kardio 365 - úvodní stránka
nepřihlášen  
Change language:    

AVAILABILITY OF ENERGETIC SUBSTRATES AND EXERCISE TOLERANCE IN HEART FAILURE WITH OR WITHOUT DIABETES

V. Melenovský, M. Kotrč, J. Polák, M. Cahová, B. Bendlová, I. Málek, P. Jarolim, L. Kazdová, J. Kautzner (Praha, Prague, Baltimore, MD, United States, Boston, United States)
Tématický okruh: Srdeční selhání, transplantace, oběhové podpory
Typ: Ústní sdělení - lékařské, XX. výroční sjezd ČKS

Aims: Due to reciprocal fuel flux regulation, elevated free fatty acids (FFA) may influence glucose utilization and efficiency of the failing heat. The goal was to address whether acute exercise-induced changes in plasma FFA and other metabolites can adversely impact cardiac performance and outcome in heart failure (HF) with or without diabetes mellitus (DM).
Methods and Results: 27 healthy controls matched with 97 patients with stable advanced HF were prospectively enrolled. Exercise capacity, age, gender and HF aetiology were balanced between HFDM- and HFDM+ groups. Subjects underwent cardiac assessment, anthropometry and maximal spiroergometry with blood sampling to address the influence of exercise dynamics of etabolites on attained cardiac performance (peak VO2) and long-term outcome. HFDM+ patients had increased resting FFA and glucose, higher insulin resistance than HFDM-, and more elevated β-OH butyrate than controls. In all HF, baseline FFA correlated with adiposity, rather than neurohumoral activation. During exercise, FFA decreased both in HFDM-(28%) and HFDM+ (-39%), but not in controls. Peak VO2 was unrelated to post-exercise FFA, glucose, lactate or glycerol, but strongly correlated with post-exercise pyruvate (r=0.62, p<0.001). During next 17±10 months, 36% patients experienced an adverse event. Diabetes (HR 1.98, p=0.04), post-exercise glucose (HR 1.28, p=0.04) and total body fat (HR 0.58, p<0.001) but not FFA were predictive of outcome.
Conclusions: FFA-mediated effects on carbohydrate utilization do not play a role in exercise limitation in HF, regardless diabetes. Inhibition of body fat depletion or increasing dynamics of plasma pyruvate may represent a therapeutic target in advanced HF.